Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases including oncology and obesity, has announced its upcoming participation at the 43rd Annual J.P. Morgan Healthcare Conference.

The company's management will deliver their presentation on January 15th, 2025, at 4:30 p.m. PT. Investors and interested parties can access a live webcast of the presentation through the investor relations page at http://ir.ternspharma.com. The presentation recording will remain available on the company's website for a minimum of 30 days following the event.

News Market Reaction – TERN

-4.48%

1 alert

-4.48% News Effect

On the day this news was published, TERN declined 4.48%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

01/08/2025 - 04:05 PM

FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will present at the 43^rd Annual J.P. Morgan Healthcare Conference on January 15^th, 2025 at 4:30 p.m. PT.

A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com

FAQ

When is Terns Pharmaceuticals (TERN) presenting at the 2025 J.P. Morgan Healthcare Conference?

Terns Pharmaceuticals will present at the J.P. Morgan Healthcare Conference on January 15th, 2025, at 4:30 p.m. PT.

How can investors watch Terns Pharmaceuticals' (TERN) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live webcast available on Terns Pharmaceuticals' investor relations website at http://ir.ternspharma.com.